Date
- 2026 (14)
- 2025 (24)
- 2024 (41)
- 2023 (48)
- 2022 (26)
- 2021 (101)
- 2020 (61)
- 2019 (126)
- 2018 (40)
- 2017 (21)
- 2016 (22)
- 2015 (14)
- 2014 (22)
- 2013 (8)
- 2012 (3)
- 2010 (2)
- 2009 (11)
- 2008 (5)
- 2007 (12)
- 2006 (10)
- 2005 (12)
- 2004 (5)
- 2003 (2)
- 2002 (6)
- 2001 (3)
- 2000 (11)
- 1999 (5)
- 1998 (4)
- 1997 (1)
- 1996 (7)
- 1995 (2)
- 1994 (6)
- 1993 (5)
- 1991 (19)
Sponsor content
699 result(s) found, displaying 1 to 10
-
Prescription medicine decision summaryTzield (teplizumab) is approved to delay the onset of Stage 3 type 1 diabetes mellitus (T1D) in adult and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes mellitus.
-
Prescription medicine decision summaryCenrifki (tolebrutinib) has been approved for the treatment of Secondary Progressive Multiple Sclerosis (SPMS) in adults.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TZIELD teplizumab 2 mg/2 mL Concentrated injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CENRIFKI tolebrutinib 60mg film coated tablet blister pack.
-
Prescription medicine registrationActive ingredients: teplizumab.
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Prescription medicine registrationActive ingredients: tolebrutinib.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Sanofi-Aventis Australia Pty Ltd - Medication transfer set.
-
Cancellation by sponsorRequested by Sanofi-Aventis Australia Pty Ltd
-
Prescription medicine registrationActive ingredients: Meningococcal polysaccharide Group Y, Meningococcal polysaccharide group A, Meningococcal polysaccharide group C, Meningococcal polysaccharide group W135.